The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.

The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and ...

While the UK continues its close 25-year partnership with Gavi, the US is halting funding to the organisation. In a move that ...

The US FDA has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use ...

Novartis has completed its previously announced acquisition of Regulus Therapeutics for $1.7bn, strengthening its renal ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump ...

The evolving landscape of vaccine oversight makes it key to maintain public trust and keep scientific integrity at the ...

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) ...

The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.